Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0USILO
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
TAC-001
|
|||||
| Synonyms |
CD22 targeting TRAAC-Tallac Therapeutics; TAAC-001; TAC 001; TAC-001
Click to Show/Hide
|
|||||
| Organization |
Tallac Therapeutics, Inc.
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Antibody Name |
Mozistobart
|
Antibody Info | ||||
| Antigen Name |
B-cell receptor CD22 (CD22)
|
Antigen Info | ||||
| Payload Name |
Differentiated TLR-9 agonist (T-CpG)
|
Payload Info | ||||
| Therapeutic Target |
Toll-like receptor 9 (TLR9)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Combination Type |
Zoratolimod
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion: Histologically/cytologically confirmed solid tumors, ECOG PS 0-1, and adequate organ function
|
||||
| Administration Dosage |
TAC-001 Single-Agent Dose-Escalation Cohorts
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05399654 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors | ||||
| Primary Endpoint |
Primary objectives include determining the RP2D of TAC-001 monotherapy in advanced/metastatic solid tumors [2 years], and evaluating preliminary efficacy through ORR (CR+PR), duration of response, and clinical benefit rate per RECIST 1.1/iRECIST [2 years].
|
||||
| Other Endpoint |
Secondary endpoints assess safety (AE/SAE/irAE incidence via CTCAE v5.0 [2 years]), pharmacokinetics (Cmax, Tmax, AUC, half-life, clearance [2 years]), and immunogenicity (ADA incidence [2 years]).
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05399654 | Clinical Status | Phase 1/2 | ||
| Clinical Description | A phase 1/2, open label, dose escalation and expansion study of TAC-001 in patients with select advanced or metastatic solid tumors. | ||||
References